Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01870206|
Recruitment Status : Unknown
Verified September 2013 by Laboratorios de Biologicos y Reactivos de México, S.A. de C.V..
Recruitment status was: Recruiting
First Posted : June 5, 2013
Last Update Posted : September 30, 2013
Polio is a highly infectious disease caused by a virus. It invades the nervous system, and can cause total paralysis in a matter of hours. The virus enters the body through the mouth and multiplies in the intestine. Initial symptoms are fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. One in 200 infections leads to irreversible paralysis (usually in the legs). Among those paralysed, 5% to 10% die when their breathing muscles become immobilized. There is no cure for polio, it can only be prevented. Polio vaccine, given multiple times, can protect a child for life.
Compare in newborns the immunogenicity and safety of the vaccine OPV produced by Birmex compared with the vaccine OPV produced by Sanofi Pasteur, both produced in Vero cells.
|Condition or disease||Intervention/treatment||Phase|
|Poliomyelitis||Biological: Trivalent OPV Birmex Biological: Trivalent OPV Sanofi Pasteur||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||320 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Phase III Immunogenicity, Safety, Poliovirus Excretion and Acceptance of Vaccination OPV (Vero Cells) in Newborns Mexicans|
|Study Start Date :||June 2013|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||January 2014|
Experimental: Trivalent OPV Birmex
Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
Biological: Trivalent OPV Birmex
Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
Other Name: tOPV
Active Comparator: Trivalent OPV Sanofi Pasteur
Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
Biological: Trivalent OPV Sanofi Pasteur
Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
Other Name: tOPV
- Change seroconversion after one dose of trivalent vaccine OPV [ Time Frame: after the first dose is taken blood samples (baseline, 30 and 60 days) ]
- Evaluate the adverse events in newborns babies [ Time Frame: inmediately after treatment and during 60 days ]
- Poliovirus Excretion [ Time Frame: Evaluate viral excretion rate, basal 7, 14, 21 and 28 days after vaccination of two vaccines against polio OPV in newborns Mexicans ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870206
|Contact: Alvaro García-Pérez, MD||5554222840 ext email@example.com|
|Hospital General de Chalco Dr. Fernando Quiroz Gutierrez||Recruiting|
|Valle de Chalco, Estado de México, Mexico, 56613|
|Principal Investigator: Monserrat Ávila-Flores, Pediatrics|
|Principal Investigator:||Mauricio Rodríguez Álvarez, PhD||Laboratorios de Biológicos y Reactivos de México S.A de C.V|